Durvalumab + Tremelimumab + Cisplatin + Gemcitabine + Carboplatin + Gemcitabine
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Unresectable Locally Advanced Urothelial Cancer
Conditions
Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
Trial Timeline
Sep 27, 2018 → Apr 29, 2026
NCT ID
NCT03682068About Durvalumab + Tremelimumab + Cisplatin + Gemcitabine + Carboplatin + Gemcitabine
Durvalumab + Tremelimumab + Cisplatin + Gemcitabine + Carboplatin + Gemcitabine is a phase 3 stage product being developed by AstraZeneca for Unresectable Locally Advanced Urothelial Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03682068. Target conditions include Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer.
What happened to similar drugs?
1 of 20 similar drugs in Unresectable Locally Advanced Urothelial Cancer were approved
Approved (1) Terminated (1) Active (18)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03682068 | Phase 3 | Active |
Competing Products
20 competing products in Unresectable Locally Advanced Urothelial Cancer